Donation enables sustainable access to hemophilia treatment

Pledge to donate up to 1 billion IUs of factor therapy over ten years to the developing world is changing the haemophilia treatment paradigm. Nearly 17,000 people have already been treated using donated factor.

The World Federation of Hemophilia (WFH) estimates that there are approximately 400,000 people living with hemophilia worldwide, with around 75% having limited or no access to treatment, particularly in the developing world. Many people with severe hemophilia in these countries do not survive to adulthood due to a lack of treatment.

Along with the World Federation of Hemophilia, Sobi and Sanofi Genzyme share a vision that every person with hemophilia should receive the treatment they need regardless of where they live.

To help turn that vision into reality, Sobi and Sanofi Genzyme continue to deliver on the 2014 pledge to produce and donate up to 1 billion international units (IUs) of extended half-life clotting factor for humanitarian use, with up to 500 million IUs being donated to the World Federation of Hemophilia Humanitarian Aid Program over five years.

Since this unprecedented donation through the WFH program began in 2015, the impact has been far-reaching:

• Over 360 million IUs of factor therapy donated
• 16,900 patients treated in 40 countries
• More than 117,000 acute bleeds treated since 2015
• Enabling nearly 2,000 surgeries, including life- and limb-saving operations
• More than doubling the percentage of children receiving treatment from 14 to 39 percent.

The donation is an important first step toward providing those most in need with a predictable and sustainable supply of hemophilia therapy. Together, Sobi and Sanofi Genzyme hope that other pharmaceutical companies, charitable foundations and government agencies will join this effort so that all people with hemophilia can have access to the treatment they need.

About hemophilia A and B

Hemophilia is a rare, genetic disorder in which the ability of a person’s blood to clot is impaired. People with hemophilia A or B experience bleeding episodes that can cause pain, irreversible joint damage and life-threatening hemorrhages.